Seagen, Astellas on track for Padcev label expansion with Phase Ib/II data

Positive top-line data for Padcev from Seagen and Astellas put the antibody-drug conjugate on track for a big label expansion into a subset of first-line urothelial cancer patients — and possibly an accelerated approval — while creating a clearer picture of Seagen’s valuation for potential acquirers.

Seagen Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (Tokyo:4503) reported that Padcev enfortumab vedotin-ejfv plus Keytruda pembrolizumab led to a 64.5% objective response rate (ORR) as first-line treatment for cisplatin-ineligible, locally advanced or metastatic urothelial cancer among the 76 patients treated with the combination in Cohort K of the Phase Ib/II EV-103 study...